Chimeric antigen receptor (CAR) T cell therapy for solid tumors has shown limited efficacy in early-phase clinical studies. The majority of CARs encode CD28 and/or 41BB costimulatory endodomains, and we explored whether MyD88 and CD40 (MC) costimulatory endodomains in CARs could improve their antitumor activity. We generated CD28-, 41BB-, and MC-CAR T cells and demonstrated that MC-CAR T cells have greater proliferative capacity and antitumor activity in repeat stimulation assays and in tumor models in vivo. Transcriptomic analysis revealed that MC-CAR T cells expressed higher levels of MYB and FOXM1, key cell cycle regulators, and were activated at baseline. After stimulation, MC-CAR T cells remained in a less differentiated state than CD28- and 41BB-CAR T cells as judged by low levels of transcription factor TBET and B lymphocyte induced maturation protein 1 expression and lower cytolytic activity in comparison with CD28- and 41BB-CAR T cells. Thus, including MyD88 and CD40 signaling domains in CARs may improve current CAR T cell therapy approaches for solid tumors.
Brooke Prinzing, Patrick Schreiner, Matthew Bell, Yiping Fan, Giedre Krenciute, Stephen Gottschalk
Title and authors | Publication | Year |
---|---|---|
Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR
Lam PY, Omer N, Wong JK, Tu C, Alim L, Rossi GR, Victorova M, Tompkins H, Lin C, Mehdi AM, Choo A, Elliott MR, Coleborn E, Sun J, Mercer T, Vittorio O, Dobson LJ, McLellan AD, Brooks A, Tuong ZK, Cheetham SW, Nicholls W, Souza\u2010Fonseca\u2010Guimaraes F |
Clinical and Translational Medicine | 2025 |
Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing
Castellanos-Rueda R, Wang KL, Forster JL, Driessen A, Frank JA, Martínez MR, Reddy ST |
Science Advances | 2025 |
Enhancing CAR T-Cell Function with Domains of Innate Immunity Sensors
Mlakar T, Skrbinek M, Fink T, Lainšček D |
International Journal of Molecular Sciences | 2025 |
Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors
Mikolič V, Pantović-Žalig J, Malenšek Š, Sever M, Lainšček D, Jerala R |
2024 | |
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Menachem A, Alteber Z, Cojocaru G, Fridman Kfir T, Blat D, Leiderman O, Galperin M, Sever L, Cohen N, Cohen K, Granit RZ, Vols S, Frenkel M, Soffer L, Meyer K, Menachem K, Galon Tilleman H, Morein D, Borukhov I, Toporik A, Perpinial Shahor M, Tatirovsky E, Mizrachi A, Levy-Barda A, Sadot E, Strenov Y, Eitan R, Jakobson-Setton A, Yanichkin N, Ferre P, Ophir E |
Cancer immunology research | 2024 |
T cell dysfunction and therapeutic intervention in cancer.
Zebley CC, Zehn D, Gottschalk S, Chi H |
Nature Immunology | 2024 |
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling MC, Cole AC, Brammer B, Diatikar KG, Schmitt NC, Paulos CM |
Cancers | 2024 |
The Multifaceted Roles of Hippo-YAP in Cardiovascular Diseases.
Wu H, Che YN, Lan Q, He YX, Liu P, Chen MT, Dong L, Liu MN |
Cardiovascular toxicology | 2024 |
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.
Wickman E, Lange S, Wagner J, Ibanez J, Tian L, Lu M, Sheppard H, Chiang J, Koo SC, Vogel P, Langfitt D, Perry SS, Shanmugam R, Bell M, Shaw TI, Krenciute G, Zhang J, Gottschalk S |
Journal for immunotherapy of cancer | 2024 |
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao Z, Chyra Z, Kotulová J, Celichowski P, Mihályová J, Charvátová S, Hájek R |
Blood Cancer Journal | 2024 |
CD47 expression is critical for CAR T-cell survival in vivo
Beckett AN, Chockley P, Pruett-Miller SM, Nguyen P, Vogel P, Sheppard H, Krenciute G, Gottschalk S, DeRenzo C |
Journal for ImmunoTherapy of Cancer | 2023 |
The role of FoxM1 in immune cells.
Zheng J, Bu X, Wei X, Ma X, Zhao P |
Clinical and Experimental Medicine | 2023 |
Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development
Zhao N, Song Y, Xie X, Zhu Z, Duan C, Nong C, Wang H, Bao R |
Signal Transduction and Targeted Therapy | 2023 |
Transcriptomic Approaches in Studies on and Applications of Chimeric Antigen Receptor T Cells
Pierzynowska K, Gaffke L, Zaucha JM, Węgrzyn G |
Biomedicines | 2023 |
Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy
McKenzie C, El-Kholy M, Parekh F, Robson M, Lamb K, Allen C, Sillibourne J, Cordoba S, Thomas S, Pule M |
2023 | |
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
Righi M, Gannon I, Robson M, Srivastava S, Kokalaki E, Grothier T, Nannini F, Allen C, Bai YV, Sillibourne J, Cordoba S, Thomas S, Pule M |
Cancer immunology research | 2023 |
Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics
Tabnak P, Hasanzade Bashkandi A, Ebrahimnezhad M, Soleimani M |
Cancer Cell International | 2023 |
Cellular and molecular waypoints along the path of T cell exhaustion
Lan X, Zebley CC, Youngblood B |
Science Immunology | 2023 |
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
B Omer, M Cardenas, T Pfeiffer, R Daum, M Huynh, S Sharma, N Nouraee, C Xie, C Tat, S Perconti, S Pelt, L Scherer, C DeRenzo, T Shum, S Gottschalk, C Arber, C Rooney |
Cancer immunology research | 2022 |
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T, Yu SK, Xiang Y, Lu KH, Sun M |
Frontiers in immunology | 2022 |
Application and Design of Switches Used in CAR
Głowacki P, Rieske P |
Cells | 2022 |
Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains
Gordon KS, Kyung T, Perez CR, Holec PV, Ramos A, Zhang AQ, Agarwal Y, Liu Y, Koch C, Starchenko A, Joughin BA, Lauffenburger DA, Irvine DJ, Hemann MT, Birnbaum ME |
Nature Biomedical Engineering | 2022 |
RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A |
Nature | 2022 |
speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.
Castellanos-Rueda R, Di Roberto RB, Bieberich F, Schlatter FS, Palianina D, Nguyen OTP, Kapetanovic E, Läubli H, Hierlemann A, Khanna N, Reddy ST |
Nature Communications | 2022 |
Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions
Ung S, Choochuen P, Khopanlert W, Maneechai K, Sangkhathat S, Terakura S, Julamanee J |
Frontiers in immunology | 2022 |
Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, Mullighan CG, Krenciute G, Chockley PJ, Naik S, Langfitt DM, Mamonkin M, Obeng EA, Thomas PG, Gottschalk S, Velasquez MP |
Blood | 2022 |
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, Bonifant CL, Cheng C, Gottschalk S, Velasquez MP |
Haematologica | 2022 |
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
J Julamanee, S Terakura, K Umemura, Y Adachi, K Miyao, S Okuno, E Takagi, T Sakai, D Koyama, T Goto, R Hanajiri, M Hudecek, P Steinberger, J Leitner, T Nishida, M Murata, H Kiyoi |
Molecular Therapy | 2021 |
Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction
B Lamarthée, A Marchal, S Charbonnier, T Blein, J Leon, E Martin, L Rabaux, K Vogt, M Titeux, M Delville, H Vinçon, E Six, N Pallet, D Michonneau, D Anglicheau, C Legendre, JL Taupin, I Nemazanyy, B Sawitzki, S Latour, M Cavazzana, I André, J Zuber |
Nature Communications | 2021 |
How Can We Engineer CAR T Cells to Overcome Resistance?
M Glover, S Avraamides, J Maher |
Biologics : targets & therapy | 2021 |
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
TN Bullock |
Cellular and Molecular Immunology | 2021 |
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
ED Bousser, N Callewaert, N Festjens |
Cancers | 2021 |
A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function
S Lange, LG Sand, M Bell, SL Patil, D Langfitt, S Gottschalk |
Cancer Discovery | 2021 |
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
Harrison AJ, Du X, von Scheidt B, Kershaw MH, Slaney CY |
2021 |